Printing a mean hammer candle on RSI divergence and a clean earnings double beat $ABBV https://t.co/R9yYhK5aXF
Buy or sell guide
Should I Buy ABBV Stock Right Now?
A fast read on Wall Street conviction, live analyst commentary on X, and current valuation context for AbbVie Inc..
Updated 2026-05-06
Wall Street currently rates ABBV buy with a 12-month price target of $257 (+25.2% upside). See live commentary from high-reach stock analysts on X, plus the bull case, key risks, and the latest earnings execution.
Wall Street
Buy41 analystsConsensus target
$257 target (+25.2%)Current price $204.98Analyst sentiment
Bullish from 1 recent analyst posts1 bull · 0 bear · 0 neutralEarnings context
EPS beat 2.3%Reported Wed Apr 29Wall Street verdict
Should I Buy ABBV Stock? Here's What Analysts Think
41 analysts currently cover ABBV. Below is their consensus rating, price target range, and implied upside.
According to 41 analysts, AbbVie Inc. (ABBV) is rated Buy with a consensus 12-month price target of $257 — representing 25% upside from today's price of $205. The bull case target is $294, the bear case is $223.
ABBVBuy
From 41 analyst ratings- Current price
- $204.98
- Consensus Target
- $257 (+25.2% upside)
- Forward P/E
- 14.4x
- Coverage
- 41 analyst ratings
High target$294
Low target$223
At $204.98, the consensus setup implies +25.2% versus the 12-month target.
- 28 of 41 analysts lean Buy or Strong Buy, while 12 stay on Hold and 1 lean bearish.
- ABBV trades at roughly 14.4x forward earnings, so the bull case still depends on growth staying strong.
- Analysts span a wide range from $223 to $294, so conviction matters as much as the consensus target.
Below, compare that institutional answer with the live analyst commentary on X for ABBV right now.
4 raised, 2 cut of 8 analystsGuggenheim $249Canaccord Genuity $265Morgan Stanley $278+5 more
May 2026Live commentary on X· Last 30 days · 1 take
What Analysts Are Saying About AbbVie Inc. Right Now
Real posts from high-reach stock analysts mentioning ABBV, shown exactly as written. Sorted by engagement — most discussed first.
Recent high-reach analyst commentary leans bullish — the loudest voices on X are giving the tape the benefit of the doubt.
Bullish·
1 Bullish0 Neutral0 Bearish
Posts sourced from high-follower stock analysts on X. Bullish/bearish signals are auto-classified; verify on the original post before acting.
Should you buy ABBV?
Is ABBV a Buy, Hold, or Sell Right Now?
A structured look at the bull case, the risks, and the most recent earnings execution for ABBV before you decide whether to buy, hold, or sell.
Current setup
ABBV beat estimates last quarter. Below are the key reasons analysts remain constructive and the risks that could change that view.
Bull Case
What keeps the long thesis intact
- Strong Growth in ImmunologyAbbVie is experiencing strong growth in immunology with drugs like Skyrizi and Rinvoq, which are expected to drive continued earnings growth.
- Positive Analyst OutlookAnalysts hold a consensus rating of 'Buy' for AbbVie, indicating confidence in the stock's future performance.
- Raised Full-Year GuidanceManagement has raised full-year guidance, reflecting confidence in AbbVie's future earnings potential.
- Promising Pipeline OpportunitiesThe company's pipeline includes promising candidates in obesity and oncology, which could provide significant future growth.
Wall Street rates ABBV buy, giving the bull case institutional backing from 41 analysts.
Watch Out For
What can break the setup quickly
- High Valuation ConcernsAbbVie has a trailing P/E ratio that is significantly higher than the industry average, raising concerns about overvaluation.
- Margin Compression RisksThere are worries about margin compression and a recent large one-off loss that negatively impacted net income.
- Vulnerability to BiosimilarsAbbVie relies heavily on a concentrated group of therapies, making it vulnerable to biosimilar competition, especially as Humira sales decline.
- Regulatory RisksThe FDA's Complete Response Letter for trenibotulinumtoxinE due to manufacturing issues presents a significant risk to AbbVie's pipeline.
Watch whether new negative commentary on ABBV points to these structural risks or is simply reacting to short-term price moves.
ABBV Earnings Reaction — What the Last Quarter Showed
Last Quarter
- EPS
- $2.65 vs $2.59 est.Beat 2.3%
- Revenue
- $15.0B vs $14.7B est.Beat 1.9%
Full ABBV Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Should I Buy ABBV Right Now?
Bull case, key risks, Wall St analyst verdict, and what council investors are saying — updated daily.
See ABBV's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ABBV Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare with Peers
Compare business quality, growth, and profitability against top sector peers.
Start ComparisonABBV — Frequently Asked Questions
Quick answers to the most common questions about buying ABBV stock.
Should I buy ABBV stock right now?
Verdict
ABBV looks attractive at current levels — Wall Street's consensus rating is "Buy" with a $257 price target (+25.2% upside from $204.98). The council of high-follower analysts on X is currently signalling bullish. This is informational only — verify the data and consider your own risk tolerance before deciding.
Is now a good time to buy ABBV?
Timing
Timing depends on your horizon, but the data signals are: consensus rating "Buy" with +25.2% upside to the $257 target. Recent activity is mixed — 4 analysts raised and 2 cut targets in the past 30 days.
What is the price target for ABBV stock?
Price Target
ABBV's consensus 12-month price target is $257, set by 41 Wall Street analysts. The bull case high is $294 and the bear case low is $223. From the current price of $204.98, this implies +25.2% upside.
Is ABBV overvalued or undervalued?
Valuation
ABBV appears undervalued — the $257 consensus target is +25.2% above today's $204.98. It trades at a forward P/E of 14.4x. Targets range from $223 (bear) to $294 (bull), reflecting different assumptions about growth and margins.
Should I buy ABBV before earnings?
Earnings
ABBV reports next quarter. Earnings-week moves are volatile — historically, analyst targets revise upward after a beat and downward after a miss. The current consensus is "Buy" with a $257 target. Consider position sizing rather than going all-in pre-print.
What are analysts saying about ABBV stock?
Coverage
Of 41 analysts covering AbbVie Inc. (ABBV): 0 Strong Buy, 28 Buy, 12 Hold, 1 Sell, 0 Strong Sell — a "Buy" consensus. The 12-month price target is $257 (range $223–$294). Bullish analysts outnumber bearish by more than 2-to-1.
What are the risks of buying ABBV stock?
Risks
1 of the 41 analysts covering ABBV rate it Sell or Strong Sell. Common concerns include valuation stretch, slowing growth, and sector-specific headwinds — see the Bull vs. Risk cards above for the specific theses on AbbVie Inc..
This page is for informational purposes only and does not constitute financial advice. Always conduct your own research before investing.